Anna Gribkova

Title: Anna Gribkova: Innovator in Tumor Microenvironment Research

Introduction

Anna Gribkova is a prominent inventor based in Moscow, Russia. She has made significant contributions to the field of immunotherapy, particularly in understanding tumor microenvironments. With a total of 2 patents, her work is paving the way for advancements in cancer treatment.

Latest Patents

One of Anna Gribkova's latest patents focuses on tumor microenvironment-based methods for assessing CAR-T and other immunotherapies. This patent outlines methods for determining whether a subject is likely to respond to adoptive cell therapies, such as chimeric antigen receptor (CAR) T-cell therapy. The methods involve identifying a subject's tumor microenvironment (TME) type based on a molecular-functional expression signature. Additionally, it includes determining the lymphoma microenvironment (LME) type for lymphoma subjects, such as those with Diffuse Large B cell lymphoma (DLBCL), to assess their prognosis.

Career Highlights

Anna Gribkova is currently associated with Bostongene Corporation, where she continues her research and development in the field of immunotherapy. Her innovative approaches are contributing to the understanding of how different tumor microenvironments affect treatment responses.

Collaborations

Anna collaborates with notable colleagues, including Georgy Sagaradze and Grigorii Nos. Their combined expertise enhances the research efforts at Bostongene Corporation.

Conclusion

Anna Gribkova is a trailblazer in the field of tumor microenvironment research, with her patents reflecting her commitment to improving cancer therapies. Her work is essential for advancing the effectiveness of immunotherapies in clinical settings.